Oral administration of genetically modified Bifidobacterium displaying HCV-NS3 multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice.

摘要: More than 170 million people worldwide are chronic HCV (Hepatitis C virus) carriers, and about 30% of them will develop progressive liver disease, such as cirrhosis hepatocellular carcinoma. A combination pegylated interferon-α with ribavirin, the standard treatment for infection, has been effective in fewer 50% patients infected genotype 1. strong T cell response against nonstructural protein 3 (NS3) is important recovery from acute an early multi-specific CD4+ helper CD8+ cytotoxic critical clearance. In present study, we successfully constructed a genetically modified Bifidobacterium longum (B. longum) displaying recombinant HCV-NS3 peptides containing some CD4 CD8 epitopes located region oral vaccine infection. The administration this could induce NS3-specific immune responses mice through intestinal mucosal immunity. Our findings suggest that novel great potential